Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes.
Management of patients with type 2 diabetes should focus on decreasing the excess macrovascular disease with which it is associated as well as preventing or minimizing microvascular disease. Near-normoglycemic control can reduce microvascular disease. Reducing macrovascular disease requires concomitant management of the cardiovascular risk factors (components of the insulin resistance syndrome) associated with type 2 diabetes. The first phase of such treatment is to identify the effects that the various drugs to treat the hyperglycemia are likely to have on these associated cardiovascular risk factors. Appropriate combinations of antihyperglycemic agents should be selected for specific patients to help achieve good glycemic control and produce beneficial, or at least nondetrimental, effects on cardiovascular risk.
Lebovitz
H E
HE
Division of Endocrinology and Metabolism, State University of New York, Brooklyn 11203, USA.
D000284:Administration, Oral; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use; D012307:Risk Factors; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D008687:Metformin